Biosimilars Switching Debate Escalates After Remicade and Remsima Match In Landmark Study
Executive Summary
Biosimilar drug makers say that the NOR-SWITCH study on switching from Johnson & Johnson’s infliximab to the Celltrion product supports the concept of biosimilarity and proves that they are subject to the same regulatory standards as originators. Originators, meanwhile, want more evidence that switching works.
You may also be interested in...
Canada Attempts Biosimilar Balancing Act
Plans to make Canada’s biologics market more competitive for biosimilars are advancing as payers are planning consultations on how price negotiations for biosimilars and biologics will proceed.
Canada Attempts Biosimilar Balancing Act
Plans to make Canada’s biologics market more competitive for biosimilars are advancing as payers are planning consultations on how price negotiations for biosimilars and biologics will proceed.
Biosimilars Boost In Europe: 2017 Kicks Off With Three Approvals And Backing From ESMO
With three new approvals in January, the first anticancer about to be authorized, and a vote of confidence from the oncology physicians’ body ESMO, the European biosimilar medicines sector already seems to be picking up momentum in 2017.